Columbia Trust Co 01012016 Purchases 39 Shares of Eli Lilly and Company (NYSE:LLY)

Columbia Trust Co 01012016 raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,056 shares of the company’s stock after purchasing an additional 39 shares during the quarter. Columbia Trust Co 01012016’s holdings in Eli Lilly and Company were worth $616,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Fairfield Bush & CO. bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $107,000. Roundview Capital LLC grew its stake in shares of Eli Lilly and Company by 2.6% during the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after acquiring an additional 53 shares during the period. Merit Financial Group LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $210,000. NewEdge Advisors LLC grew its stake in shares of Eli Lilly and Company by 9.9% during the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after acquiring an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. bought a new position in Eli Lilly and Company in the 1st quarter worth approximately $561,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wells Fargo & Company upped their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Bank of America upped their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $689.52.

Eli Lilly and Company Trading Up 0.3 %

LLY stock traded up $2.05 during midday trading on Tuesday, reaching $775.19. The company’s stock had a trading volume of 2,098,618 shares, compared to its average volume of 3,252,679. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a fifty day simple moving average of $725.15 and a two-hundred day simple moving average of $634.68. Eli Lilly and Company has a 1 year low of $323.26 and a 1 year high of $800.78. The firm has a market capitalization of $736.55 billion, a price-to-earnings ratio of 133.65, a PEG ratio of 1.69 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.09 earnings per share. On average, equities research analysts predict that Eli Lilly and Company will post 12.42 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 195,055 shares of company stock valued at $125,254,657. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.